Article Sidebar

Submitted
7 January 2022
Accepted
1 March 2022
Published
7 March 2022
Download
PDF
Statistic
Read Counter : 603 Download : 281

Main Article Content

Abstract

Highlight:

  1. Assessing the survival rate in castration-resistant prostate cancer was descriptived.
  2. PSA level between survivor and non survivor was significant but not for PSA nadir level, TTN and TTC.
  3. Initial PSA level can predict survival prognosis rate of castration-resistant prostate cancer patients.
 

Abstract:

High mortality rates was often found in castration-resistant prostate cancer (CRPC). Our aim on this research was to assess the PSA level and time to PSA nadir as a prognostic tool for survival in CRPC patients. Several factors are considered to be useful as prognostic marker in CRPC patients. This study was a descriptive study assessing the survival rate in castration-resistant prostate cancer. Evaluation data included sex, age, initial PSA level, final PSA level, time to PSA nadir (TTN), time to CRPC progression (TTC), and survival status. A total of 24 patients with CRPC were evaluated in this study. There was significant difference found of initial PSA level between survivor (445.7 + 165.6 ng/mL) and non-survivor (200.7 + 144.9 ng/mL). There were no significant differences were also found in PSA nadir level, TTN and TTC between survivor and non-survivor groups. This study revealed that there was association between initial PSA level on survival rate of CRPC patients. Initial PSA level could be used to predict survival prognosis in CRPC patients.

Keywords

Prostate specific antigen PSA nadir prostate cancer castration-resistant prostate cancer

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Pranata, F. H., Djatisoesanto, W., & Soebadi, D. M. (2022). Prostate-Specific Antigen and Time to PSA Nadir as Prognostic Significance in Castration-Resistant Prostate Cancer. Folia Medica Indonesiana, 58(1), 50–55. https://doi.org/10.20473/fmi.v58i1.32649
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Barsouk A, Padala SA, Vakiti A, et al (2020). Epidemiology, staging and management of prostate cancer. Med. Sci 8, 1-13.
  2. Benaim EA, Pace CM, Lam PM, et al (2002). Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 59, 73–78.
  3. Bournakis E, Efstathiou E, Varkaris A, et al (2011). Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res. 31, 1475–1482.
  4. Bray F, Ferlay J, Soerjomataram I, et al (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 68, 394-424.
  5. Choueiri TK, Xie W, D’Amico AV, et al (2009). Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy. Cancer Interdiscip. Int. J. Am. Cancer Soc. 115, 981–987.
  6. Frees S, Akamatsu S, Bidnur S, et al (2018). The impact of time to metastasis on overall survival in patients with prostate cancer. World J. Urol. 36, 1039–1046.
  7. Hamano I, Hatakeyama S, Narita S, et al (2019). Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer. World J. Urol. 37, 2365–2373.
  8. Heidegger I, Fritz J, Klocker H, et al (2015). Age-adjusted PSA levels in prostate cancer prediction: Updated results of the tyrol prostate cancer early detection program. PLoS One 10, 1-12.
  9. Huang S, Bao B, Wu M, et al (2011). Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy. Prostate 71, 1189–1197.
  10. Ilic D, Djulbegovic M, Jung JH, et al (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: A systematic review and meta-analysis. BMJ 362, 1-35.
  11. Iwamoto H, Izumi K, Kadono Y, et al (2019). Prognosis of patients with prostate cancer and middle range prostate-specific antigen levels of 20–100 ng/mL. Int. Braz J Urol 45, 61–67.
  12. Kan H-C, Hou C-P, Lin Y-H, et al (2017). Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis. Onco. Targets. Ther. 10, 2943-2949.
  13. Lowrance WT, Murad MH, Oh WK, et al (2018). Castration-resistant prostate cancer: AUA guideline amendment 2018. J. Urol. 200, 1264–1272.
  14. McAninch JW, Lue TF (2020). Smith and Tanagho’s general urology, 19th Edition. McGraw-Hill Education/Medical, New York.
  15. Ørsted DD, Nordestgaard BG, Jensen GB, et al (2012). Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur. Urol. 61, 865–874.
  16. Sasaki T, Onishi T, Hoshina A (2011). Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis. 14, 248–252.
  17. Sasaki T, Sugimura Y (2018). The importance of time to prostate-specific antigen (PSA) nadir after primary androgen deprivation therapy in hormone-naive prostate cancer patients. J. Clin. Med. 7, 1-21.
  18. Tomioka A, Tanaka N, Yoshikawa M, et al (2014). Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol. 14, 1–6.